Compare ATHM & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATHM | KARD |
|---|---|---|
| Founded | 2008 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2013 | 2026 |
| Metric | ATHM | KARD |
|---|---|---|
| Price | $21.93 | $21.62 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 717.7K | 232.4K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.57 | $19.41 |
| 52 Week High | $29.92 | $27.00 |
| Indicator | ATHM | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 53.88 |
| Support Level | $20.75 | $21.68 |
| Resistance Level | $22.47 | $22.61 |
| Average True Range (ATR) | 0.74 | 1.40 |
| MACD | -0.12 | 0.12 |
| Stochastic Oscillator | 46.02 | 66.00 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.